Christine M Borges1, Preeti Pathela1, Robert Pirillo2, Susan Blank3. 1. New York City Department of Health and Mental Hygiene, Bureau of Sexually Transmitted Disease Control, Queens, NY. 2. New York City Department of Health and Mental Hygiene, Bureau of Public Health Laboratory, Queens, NY. 3. New York City Department of Health and Mental Hygiene, Bureau of Sexually Transmitted Disease Control, Queens, NY ; Centers for Disease Control and Prevention, Division of Sexually Transmitted Disease Prevention, Atlanta, GA.
Abstract
OBJECTIVE: Staff at public New York City sexually transmitted disease (STD) clinics screen patients for acute HIV infection (AHI) using pooled nucleic acid amplification tests. AHI screening is expensive but important for populations at high risk of acquiring HIV. We analyzed if targeting AHI screening in STD clinics could reduce program costs while maintaining AHI case detection. METHODS: From January 2009 through May 2010, we screened all patients with negative rapid HIV tests for AHI. Using risk information on cases detected during this universal screening period, we developed criteria for targeted AHI screening and compared case yields and testing costs during 12 months of universal screening (June 2009 through May 2010) vs. 12 months of targeted screening (June 2010 through May 2011). RESULTS: During the defined period of universal screening, we identified 40 AHI cases, and during targeted screening, we identified 35 AHI cases. Because of targeting efforts, the number needed to test to find one AHI case dropped from 1,631 to 254. With targeted screening, it cost an average of $4,535 per case detected and 39.3 cases were detected per 10,000 specimens; using universal screening, $29,088 was spent per case detected and 6.1 cases were detected per 10,000 specimens processed. CONCLUSION: Targeted screening identified similar numbers of AHI cases as when screening all clinic patients seeking HIV testing, but at one-seventh the cost.
OBJECTIVE: Staff at public New York City sexually transmitted disease (STD) clinics screen patients for acute HIV infection (AHI) using pooled nucleic acid amplification tests. AHI screening is expensive but important for populations at high risk of acquiring HIV. We analyzed if targeting AHI screening in STD clinics could reduce program costs while maintaining AHI case detection. METHODS: From January 2009 through May 2010, we screened all patients with negative rapid HIV tests for AHI. Using risk information on cases detected during this universal screening period, we developed criteria for targeted AHI screening and compared case yields and testing costs during 12 months of universal screening (June 2009 through May 2010) vs. 12 months of targeted screening (June 2010 through May 2011). RESULTS: During the defined period of universal screening, we identified 40 AHI cases, and during targeted screening, we identified 35 AHI cases. Because of targeting efforts, the number needed to test to find one AHI case dropped from 1,631 to 254. With targeted screening, it cost an average of $4,535 per case detected and 39.3 cases were detected per 10,000 specimens; using universal screening, $29,088 was spent per case detected and 6.1 cases were detected per 10,000 specimens processed. CONCLUSION: Targeted screening identified similar numbers of AHI cases as when screening all clinic patients seeking HIV testing, but at one-seventh the cost.
Authors: Pragna Patel; Berry Bennett; Timothy Sullivan; Monica M Parker; James D Heffelfinger; Patrick S Sullivan Journal: J Clin Virol Date: 2012-02-29 Impact factor: 3.168
Authors: Preeti Pathela; Sarah L Braunstein; Julia A Schillinger; Colin Shepard; Monica Sweeney; Susan Blank Journal: J Acquir Immune Defic Syndr Date: 2011-12-01 Impact factor: 3.731
Authors: T C Quinn; R Brookmeyer; R Kline; M Shepherd; R Paranjape; S Mehendale; D A Gadkari; R Bollinger Journal: AIDS Date: 2000-12-01 Impact factor: 4.177
Authors: William C Miller; Peter A Leone; Sandra McCoy; Trang Q Nguyen; Delbert E Williams; Christopher D Pilcher Journal: AIDS Date: 2009-04-27 Impact factor: 4.177
Authors: Mark M Manak; Leigh Anne Eller; Jennifer Malia; Linda L Jagodzinski; Rapee Trichavaroj; Joseph Oundo; Cornelia Lueer; Fatim Cham; Mark de Souza; Nelson L Michael; Merlin L Robb; Sheila A Peel Journal: J Clin Microbiol Date: 2017-04-19 Impact factor: 5.948
Authors: Chitra Ramaswamy; Tanya M Ellman; Julie Myers; Ann Madsen; Kent Sepkowitz; Colin Shepard Journal: Open Forum Infect Dis Date: 2015-09-30 Impact factor: 3.835
Authors: Shaun Palmer; Maartje Dijkstra; Johannes Cf Ket; Elizabeth W Wahome; Jeffrey Walimbwa; Evanson Gichuru; Elise M van der Elst; Maarten F Schim van der Loeff; Godelieve J de Bree; Eduard J Sanders Journal: J Int AIDS Soc Date: 2020-10 Impact factor: 5.396